Rockefeller Capital Management
COGT icon

Rockefeller Capital Management’s Cogent Biosciences COGT Stock Holding History

Rockefeller Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.8K Hold
1,468
– – ﹤0.01% 3302
2026
Q1 		$56.5K Buy
1,468
+1,143
+352% +$42.2K ﹤0.01% 3210
2025
Q4 		$11.5K Buy
+325
New +$9.14K ﹤0.01% 3746

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rockefeller Capital Management's COGT Position: Q2 2026 in Review

Rockefeller Capital Management held its Cogent Biosciences (COGT) position steady in Q2 2026 at 1,468 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3302.

Rockefeller Capital Management first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Rockefeller Capital Management held 1,468 shares of Cogent Biosciences worth $56.8K as of Q2 2026.
  • Rockefeller Capital Management left its Cogent Biosciences share count unchanged in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3302 holding.
  • Rockefeller Capital Management first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.